StockNews.com Initiates Coverage on DURECT (NASDAQ:DRRX)
Equities research analysts at StockNews.com began coverage on shares of DURECT (NASDAQ:DRRX – Get Free Report) in a note issued to investors on Tuesday. The firm set a “sell” rating on the specialty pharmaceutical company’s stock. Separately, HC Wainwright reaffirmed a “neutral” rating on shares of DURECT in a research note on Thursday, November 14th. […]
More Stories
GEN Restaurant Group, Inc. (NASDAQ:GENK) Short Interest Down 5.0% in January
GEN Restaurant Group, Inc. (NASDAQ:GENK – Get Free Report) saw a large decline in short interest in January. As of...
General Mills Sees Unusually Large Options Volume (NYSE:GIS)
General Mills, Inc. (NYSE:GIS – Get Free Report) saw unusually large options trading activity on Tuesday. Stock traders bought 10,604...
Outlook Therapeutics’ (OTLK) Neutral Rating Reaffirmed at Chardan Capital
Chardan Capital reiterated their neutral rating on shares of Outlook Therapeutics (NASDAQ:OTLK – Free Report) in a research note released...
BigBear.ai Target of Unusually High Options Trading (NYSE:BBAI)
BigBear.ai Holdings, Inc. (NYSE:BBAI – Get Free Report) was the target of some unusual options trading on Wednesday. Stock traders...
HC Wainwright Reiterates “Buy” Rating for OKYO Pharma (NASDAQ:OKYO)
HC Wainwright reiterated their buy rating on shares of OKYO Pharma (NASDAQ:OKYO – Free Report) in a research report report...
HC Wainwright Has Lowered Expectations for Outlook Therapeutics (NASDAQ:OTLK) Stock Price
Outlook Therapeutics (NASDAQ:OTLK – Free Report) had its price objective reduced by HC Wainwright from $30.00 to $3.00 in a...